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Hexanucleotide repeat expansions in C9ORF72 cause neurodegeneration in FTD and ALS by unknown
mechanisms. A new report, by Donnelly et al. (2013), finds that these repeats trigger a pathogenic gain-of-
function cascade that can be corrected by suppressing expression of the repeat transcript, paving the
way for therapeutic strategies aimed at eliminating the toxic RNA.Frontotemporal dementia (FTD) and
amyotrophic lateral sclerosis (ALS) are
fatal neurodegenerative disorders that
share overlapping pathologies, genetic
causes, and a lack of disease-modifying
treatments (Ling et al., 2013). Precisely
two years ago, adjoining papers in
Neuron identified large intronic GGGGCC
repeat expansions in a gene of unknown
function, C9orf72, as a common genetic
cause of both FTD and ALS (C9FTD/
ALS) (Renton et al., 2011; DeJesus-Her-
nandez et al., 2011). The discovery
sparked great interest in the field, partly
because the C9orf72 expansion looked a
lot like something scientists had seen
before: the CUG and CCUG repeats that
cause the common dominantly inherited
muscle diseasemyotonic dystrophy (DM).
Work over the past 20 years has
demonstrated that repeat expansions in
two genes, a CUG repeat in DMPK
(in DM1) and a CCUG repeat in ZF9
(in DM2), elicit dominantly inherited dis-
ease through a ‘‘toxic RNA’’ gain-of-func-
tion mechanism: as RNA, the expanded
repeats bind to splicing factors, inhi-
biting their normal functions. In DM1, for
example, the expanded CUG repeat
binds Muscleblind-Like (MBNL) RNA
binding proteins, sequestering them in
nuclear foci and causing abnormal
splicing of key transcripts in muscle and
brain. Mice lacking MBNL1 or MBNL2
recapitulate disease features of DM1,
and conversely, boosting MBNL protein
expression suppresses CUG repeat-
associated toxicity in model systems
(reviewed in Lee and Cooper, 2009).
These findings laid the groundwork for
successful preclinical trials using anti-
sense oligonucleotides (ASOs) to elimi-
nate the toxic CUG repeat RNA in mouse
models (Wheeler et al., 2012), with plansfor a follow-up clinical trial in DM1 patients
soon.
By contrast, how the GGGGCC repeat
expansion triggers C9FTD/ALS is less
clear for at least three reasons. First,
the case for RNA toxicity in C9FTD/ALS
is incomplete. Although GGGGCC RNA
foci are present in disease tissues, it
remains uncertain whether proteins are
bound by the RNA repeat to a degree
that would impair normal functions. Ex-
periments that rescue disease features
by overexpressing specific sequestered
proteins or recapitulate disease features
by knocking down the same seques-
tered proteins have not been reported.
Second, expression of C9orf72 mRNA
in C9FTD/ALS patients is reduced
by 50% (DeJesus-Hernandez et al.,
2011, Gijselinck et al., 2012) and the
expanded repeat and neighboring CpG
islands are hypermethylated (Xi et al.,
2013), consistent with transcriptional
silencing of the mutant allele and a po-
tential loss of function model of disease
pathogenesis. Third, a major cellular
pathological hallmark of C9FTD/ALS,
cytoplasmic aggregates that stain posi-
tively for the P62 protein, appear to
result from protein translation through
the hexanucleotide repeat (Mori et al.,
2013b; Ash et al., 2013) via a recently
discovered process known as (repeat
associated non-AUG) RAN translation
(Zu et al., 2011). RAN translation gener-
ates unconventional protein products
from some disease-causing repeats, in-
cluding at least CAG and CUG repeats
in spinocerebellar ataxia type 8 and
CGG repeats in fragile X-associated
tremor/ataxia syndrome (Zu et al., 2011;
Todd et al., 2013). In C9FTD/ALS, the
GGGGCC repeat in all three reading
frames generates dipeptide repeat-con-Neuron 80taining proteins that presumably are
prone to aggregate.
So what is the toxic mechanism in
C9ALS/FTD: too much toxic RNA, too
much RAN translated protein, or not
enough C9orf72 protein? In this issue,
Donnelly et al. (2013) address this ques-
tion by using induced pluripotent stem
cells (iPSCs) derived from C9ALS/FTD
patients and marshaling a wide range
of techniques. They first established
that C9ALS/FTD iPSC-derived neurons
exhibit three important pathologic fea-
tures present in patients: decreased
C9orf72 mRNA, nuclear and cytoplasmic
GGGGCC RNA foci, and expression
of at least one RAN product (Gly-Pro
dipeptide), consistent with a previously
published report (Almeida et al., 2013).
C9 iPSC-derived neurons also exhibit
enhanced sensitivity to glutamate excito-
toxicity (long suspected as a contributor
to selective neuronal vulnerability in
ALS), and an altered transcriptional pro-
file that partially overlaps with transcrip-
tional changes observed in iPSC neurons
derived from mutant SOD1 ALS patients
and in C9 FTD autopsy tissues. (An
intriguing peripheral observation is that
the vast transcriptional differences in
C9ALS/FTD neurons versus SOD1 neu-
rons suggest that these two forms of
ALS are quite different molecular beasts.)
In parallel, the authors used proteome
arrays to identify 19 proteins that can
associate with GGGGCC repeats in vitro,
then focused on one identified protein,
ADARB2, as a potential RNA target.
ADAR proteins are intriguing candidates
because they participate in RNA editing
and are highly expressed in the nervous
system. ADARB2 colocalizes with GGGG
CC RNA foci in C9 iPSCs and in pa-
tient samples, and ADARB2 knockdown, October 16, 2013 ª2013 Elsevier Inc. 257
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ing that ADARB2 and the RNA repeat
functionally interact in vivo.
The best insights into pathogenesis
emerged when a series of ASOs were
used to suppress C9orf72 RNA expres-
sion. Both repeat and non-repeat-target-
ing ASOs led to significant reversals in
many of the observed phenotypes in
C9 iPS neurons, including suppression
of glutamate-induced toxicity, reduction
in RNA foci formation, and correction of
a small subset of the observed transcrip-
tional changes. Importantly, for at least
one non-repeat-associated ASO, these
improvements occurred despite a further
decrease in detectable C9orf72 mRNA
expression.
Overall, these findings suggest that
the expanded GGGGCC repeat triggers
toxicity predominantly through a toxic
gain of function rather than a loss of
C9orf72 protein function. Consistent with
this view, a recent study reported a pa-
tient homozygous for the C9 mutation
who, outside of enhanced P62 inclu-
sion burden and markedly decreased
C9orf72 RNA expression (25% of
normal), displayed a FTD clinical pheno-
type resembling heterozygous carriers
in the same family (Fratta et al., 2013).
Together, these studies support a model
in which the expanded GGGGCC repeat,
as RNA, and with or without associated
RAN-translated proteins, is a driving force
in C9 FTD/ALS disease pathogenesis.
A critical implication is that therapeutics
targeting elimination of the repeat RNA
in C9FTD/ALS patients are likely to be
beneficial, though the impact of markedly
and chronically lowering C9orf72 expres-
sion in vivo still remains to be determined.
Despite these advances, significant
work remains. Although iPSCs offer sig-
nificant advantages as models, the lack
of in vivo context potentially can skew
results and assumptions, which still re-
quire validation in animal model systems.
Similarly, the impact of C9orf72 loss over258 Neuron 80, October 16, 2013 ª2013 Elsea longer time and in control neurons will
be important next steps in the validation
of ASO based therapeutic approaches.
Moreover, the potential pathogenic role
of RAN-translated peptides remains an
open question. Although Donnelly et al.
(2013) demonstrate rapid resolution of
RNA foci yet the continued presence of
RAN-translated protein signal in C9 iPS
neurons treated with ASOs, this result
does not preclude a role for continually
produced RAN products in ongoing
neurotoxicity. Indeed, whether newly
synthesized soluble oligomers versus
higher-order aggregates are toxic to
neurons remains unresolved in many
neurodegenerative diseases and is only
now being addressed for RAN-translated
proteins. Further, while several groups
have identified GGGGCC repeat-associ-
ated RNA binding proteins (Mori et al.,
2013a; Reddy et al., 2013; Xu et al.,
2013), and the ADARB2 studies here
represent an encouraging step, the field
now needs to demonstrate that seques-
tration of specific factors is necessary
and sufficient to recapitulate aspects of
the clinical syndrome. Finally, these types
of iPSC models from patients with ALS
or FTD may allow scientists to make
headway in their pursuit of the elusive
factors driving selective and differential
neuronal vulnerability. Comparing dif-
ferent classes of iPS neurons derived
from different clinical phenotypes within
the same family may provide a route
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